KRAS Mutation-Related Tumors Clinical Trials

14 clinical trials for KRAS Mutation-Related Tumors across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies — RECRUITING · PHASE1
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — RECRUITING · PHASE1
• NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors — RECRUITING · PHASE1
• Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies — ACTIVE_NOT_RECRUITING · NA
• A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer — COMPLETED · PHASE1
• Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer — COMPLETED · PHASE2
• Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer — TERMINATED · PHASE1
• Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers — TERMINATED · PHASE1
• Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC — NOT_YET_RECRUITING · PHASE1
• A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors — TERMINATED · PHASE1
• A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours — OTHER · PHASE1
• Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model — OTHER
• Patogenic Mutation in 5 Genes — COMPLETED
• CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer — COMPLETED · NA

Refine this search